Apyx Medical(US:APYX)2025-11-06 12:02Revenue Performance - Total revenue for Q3 2025 increased to $12.9 million, up 12.1% from $11.5 million in Q3 2024[8] - Surgical Aesthetics revenue rose 19.1% to $11.1 million, compared to $9.3 million in the same quarter last year, with over 30% growth in the U.S.[6][8] - OEM revenue decreased by 17.6% to approximately $1.8 million, down from $2.2 million in Q3 2024[6][8] - Full year 2025 total revenue guidance increased to a range of $50.5 million to $52.5 million, up from previous guidance of $50.0 million to $52.0 million[14] - Surgical Aesthetics revenue for FY2025 is expected to be in the range of $43.0 million to $45.0 million, compared to approximately $38.6 million reported for FY2024[14] - Sales for the three months ended September 30, 2025, were $12,877 million, a 12.1% increase from $11,487 million in the same period of 2024[24] Profitability and Loss - Net loss attributable to stockholders narrowed to $2.0 million, or $0.05 per share, compared to a net loss of $4.7 million, or $0.14 per share, in Q3 2024[13] - Adjusted EBITDA loss decreased 96% to $0.1 million for Q3 2025, compared to $2.4 million for Q3 2024[13] - Gross profit for Q3 2025 increased to $8.3 million, with a gross margin of 64.4%, up from 60.5% in the prior year[9] - Gross profit for the three months ended September 30, 2025, was $8,297 million, compared to $6,954 million in 2024, reflecting a gross margin improvement[24] - The net loss attributable to stockholders for the three months ended September 30, 2025, was $1,984 million, an improvement from a net loss of $4,703 million in the same period of 2024[24] - Adjusted EBITDA for the three months ended September 30, 2025, was $(91) million, compared to $(2,449) million in Q3 2024, indicating a significant reduction in losses[29] Expenses and Cost Management - Operating expenses decreased by $1.5 million to $9.1 million in Q3 2025, compared to $10.6 million in Q3 2024[11] - Research and development expenses decreased to $801 million in Q3 2025 from $1,142 million in Q3 2024, a reduction of 29.9%[24] Balance Sheet and Cash Flow - Total current assets as of September 30, 2025, were $48,788 million, down from $56,440 million at the end of 2024[26] - Total liabilities increased to $51,285 million as of September 30, 2025, compared to $50,507 million at the end of 2024[26] - Cash and cash equivalents decreased to $25,135 million as of September 30, 2025, from $31,741 million at the end of 2024[26] - The accumulated deficit increased to $(87,823) million as of September 30, 2025, from $(77,911) million at the end of 2024[26] Product Launch - Apyx Medical initiated a full U.S. commercial launch of the AYON Body Contouring System™ in September 2025, with pre-orders exceeding expectations[6][8]